OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
18
Results
Show all
Save search
Copy query
Show results for
Unknown
(18)
Publication Date
Release Date
2022
(3)
2018
(3)
2019
(2)
2014
(2)
2025
(1)
2024
(1)
2023
(1)
2021
(1)
2020
(1)
2017
(1)
2015
(1)
2011
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas.
Not available
S-EPMC6256323
|
biostudies-literature
Cite
Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene.
Not available
S-EPMC5537488
|
biostudies-literature
Cite
Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas.
Not available
S-EPMC10511602
|
biostudies-literature
Cite
Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
Not available
S-EPMC7000715
|
biostudies-literature
Cite
Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel.
Not available
S-EPMC8533527
|
biostudies-literature
Cite
Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma.
Not available
S-EPMC9734219
|
biostudies-literature
Cite
Melanoma immunotherapy.
Not available
S-EPMC4049781
|
biostudies-literature
Cite
Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.
Not available
S-EPMC5808022
|
biostudies-literature
Cite
Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series.
Not available
S-EPMC6124774
|
biostudies-literature
Cite
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Not available
S-EPMC4254519
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets